BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 35485833)

  • 1. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
    Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
    Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Neoadjuvant Therapy Significantly Increases Complete Clinical Response.
    Rettig RL; Beard BW; Ryoo JJ; Kulkarni S; Gulati M; Tam M; Attaluri V
    Dis Colon Rectum; 2023 Mar; 66(3):374-382. PubMed ID: 35239525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Modified FOLFOXIRI With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score-Matched Comparison With Chemoradiotherapy.
    Zhang J; Li J; Huang M; Xie X; Cai Y; Hu H; Ling J; Wu Z; Deng Y
    Dis Colon Rectum; 2023 Jul; 66(7):934-945. PubMed ID: 35834598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Role for Neoadjuvant Systemic Therapy for cT4bM0 Colon Cancer? A Propensity Score-Matched Analysis of the National Cancer Database.
    Kamel MK; Shchatsko A; Keane CA; Serpa E; Al-Qudah G; Rahouma M; Nituica C; Blebea J; Marar O
    Dis Colon Rectum; 2023 Nov; 66(11):1435-1448. PubMed ID: 36876973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Lymphatic Invasion, Venous Invasion, Perineural Invasion, and Tumor Budding in Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision.
    Kim S; Huh JW; Lee WY; Yun SH; Kim HC; Cho YB; Park YA; Shin JK
    Dis Colon Rectum; 2023 Jul; 66(7):905-913. PubMed ID: 35195558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Course Radiotherapy Followed by Consolidation Chemotherapy Is Safe and Effective in Locally Advanced Rectal Cancer: Comparative Short-term Results of Multicenter Propensity Score Case-Matched Study.
    Benlice C; Koc MA; Gulcu B; Bilgin IA; Akyol C; Baca B; Ozturk E; Guney Y; Utkan G; Er O; Agaoglu F; Yildirim I; Avci N; Elhan AH; Kuzu MA
    Dis Colon Rectum; 2023 May; 66(5):681-690. PubMed ID: 36856669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response.
    Lai SH; Vogel JD; Vemuru S; Messersmith W; Lieu C; McCarter MD; Birnbaum E; Chapman BC
    Dis Colon Rectum; 2023 Jul; 66(7):983-993. PubMed ID: 36602514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Therapy in Stage II/III Rectal Cancer: A Retrospective Study in a Disparate Population and the Effect on Survival.
    Gan T; Chen Q; Huerta CT; Huang B; Evers BM; Patel JA
    Dis Colon Rectum; 2021 Oct; 64(10):1212-1221. PubMed ID: 34516443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging in Advanced Rectal Cancers: A Propensity-Matched Comparison Between Short-Course Radiotherapy Followed by Chemotherapy and Long-Course Chemoradiotherapy.
    Kammar PS; Garach NR; Masillamany S; de'Souza A; Ostwal V; Saklani AP
    Dis Colon Rectum; 2022 Oct; 65(10):1215-1223. PubMed ID: 34907988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Surgical Outcomes and Quality-of-Life Outcomes in Pelvic Exenteration Between Locally Advanced Versus Locally Recurrent Rectal Cancers.
    Huang Y; Steffens D; Koh CE; Young JM; Solomon MJ
    Dis Colon Rectum; 2022 Dec; 65(12):1475-1482. PubMed ID: 35913831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Sarcopenia Predict Local Response Rates After Chemoradiotherapy for Locally Advanced Rectal Cancer?
    Bedrikovetski S; Traeger L; Vather R; Sammour T; Moore JW
    Dis Colon Rectum; 2023 Jul; 66(7):965-972. PubMed ID: 36538702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
    Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.
    Jimenez-Rodriguez RM; Quezada-Diaz F; Hameed I; Kalabin A; Patil S; Smith JJ; Garcia-Aguilar J
    Dis Colon Rectum; 2021 Dec; 64(12):1463-1470. PubMed ID: 34508014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy.
    Chapman BC; Lai SH; Friedrich T; Lieu CH; Moskalenko M; Olsen JR; Herter W; Birnbaum EH; McCarter MD; Vogel JD
    Dis Colon Rectum; 2023 Apr; 66(4):521-530. PubMed ID: 34984995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limits of Clinical Restaging in Detecting Responders After Neoadjuvant Therapies for Rectal Cancer.
    Deidda S; Spolverato G; Capelli G; Bao RQ; Bettoni L; Crimì F; Zorcolo L; Pucciarelli S; Restivo A
    Dis Colon Rectum; 2023 Jul; 66(7):957-964. PubMed ID: 36538694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer.
    Xu Z; Valente MA; Sklow B; Liska D; Gorgun E; Kessler H; Rosen DR; Steele SR
    Dis Colon Rectum; 2023 Jul; 66(7):1022-1028. PubMed ID: 36538720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Multicenter Phase II Study on the Feasibility and Efficacy of S-1 and Oxaliplatin Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Sakamoto Y; Morohashi H; Miura T; Tsutsumi S; Takahashi S; Hirama K; Wakiya T; Hakamada K
    Dis Colon Rectum; 2022 May; 65(5):663-671. PubMed ID: 33833145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed TME Surgery in a Watch-and-Wait Strategy After Neoadjuvant Chemoradiotherapy for Rectal Cancer: An Analysis of Hospital Costs and Surgical and Oncological Outcomes.
    Meyer VM; Meuzelaar RR; Schoenaker IJH; de Groot JB; Reerink O; de Vos Tot Nederveen Cappel WH; Beets GL; van Westreenen HL
    Dis Colon Rectum; 2023 May; 66(5):671-680. PubMed ID: 34856587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplexed Immunofluorescence Imaging Reveals an Immune-Rich Tumor Microenvironment in Mucinous Rectal Cancer Characterized by Increased Lymphocyte Infiltration and Enhanced Programmed Cell Death Protein 1 Expression.
    Duggan WP; Kisakol B; O'Connell E; Matveeva A; O'Grady T; McDonough E; Lindner AU; McNamara D; Longley D; Ginty F; Burke JP; Prehn JHM
    Dis Colon Rectum; 2023 Jul; 66(7):914-922. PubMed ID: 36525395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy.
    Chapman WC; Kim H; Bauer P; Makhdoom BA; Trikalinos NA; Pedersen KS; Glasgow SC; Mutch MG; Silviera ML; Roy A; Parikh PJ; Hunt SR
    Dis Colon Rectum; 2022 Feb; 65(2):198-206. PubMed ID: 34990423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.